Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

EPA Regulations on Agricultural Biotechnology
--Pesticide Registration Improvement Act Reauthorization

Livestock Cloning/Product Labeling
--Discussions with EU on Animal Cloning

Genetically Engineered (GE) Animals
--Labeling
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
---Amendment on GE Salmon Labeling

Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Funding for the USDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Foreign Agricultural Biotechnology Laws and Regulations
--Asynchrony of International Approvals
--China Biotechnology Regulations
--EU Ag-Biotech Policies and Regulations

Potential Regulation of New Genetic Modification Technologies

USDA/APHIS Agricultural Biotechnology Regulations
--Efficient Science-Based Review of Biotech Products

International Treaty on Plant Genetic Resources

Review of the Federal Coordinated Framework for Biotechnology Products

17. House(s) of Congress and Federal agencies Check if None

Agriculture - Dept of (USDA), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Livestock Cloning/Product Labeling
--Discussions with EU on Animal Cloning

Genetically Engineered (GE) Animals
--Labeling
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
---Amendment on GE Salmon Labeling

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Funding for the USDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Funding for FDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Funding for the National Institutes of Health
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Funding for Centers for Disease Control and Prevention Vaccine Programs
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Funding for Renewable Chemicals/Bio-based Products
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014, Section 9003

Funding for Biofuels
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Sequestration of PDUFA Fees
--S. 1413: FDA User Fee Protection Act
--HR 2725: Food and Drug Administration Safety over Sequestration Act of 2015

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Renewable Chemicals/Bio-based Products (Non-Funding)
--S. 697: Chemical Safety for the 21st Century Act
----Nomenclature Usage
----Pre-market Notification Review
--S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
--H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015
--Expansion of Master Limited Partnerships to Renewable Chemicals
--Implementation of the Agricultural Act of 2014, Section 9003

Funding for Renewable Chemicals/Bio-based Products
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014, Section 9003

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Patent Reform
--H.R. 9: Innovation Act
--S.1137: Protecting American Talent and Entrepreneurship Act of 2015
--Implementation of the America Invents Act of 2011

TransPacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
--Regulatory Transparency

Transatlantic Trade and Investment Partnership
--Intellectual Property Issues

Drug Patent Settlements
--S.1137: Protecting American Talent and Entrepreneurship Act of 2015
--S. 2019: Preserve Access to Affordable Generics Act of 2015

Inter Partes Review
--Implementation of the American Invents Act of 2011
--S. 632: STRONG Patents Act
--S. 1137: Protecting American Talent and Entrepreneurship Act of 2015
--H.R. 9: Innovation Act

Intellectual Property International Enforcement
--India

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Livestock Cloning/Product Labeling
--Discussions with EU on Animal Cloning

Genetically Engineered (GE) Animals
--Labeling
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
---Amendment on GE Salmon Labeling

Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Biosimilars
--Colombia Biologics Regulations
--Implementation of Affordable Care Act
--Interchangeability and Pharmacy Substitution
--Naming

USDA/APHIS Agricultural Biotechnology Regulations
--Efficient Science-Based Review of Biotech Products

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
--Production Tax Credit Extension
--S.2089: American Energy Innovation Act

Funding for Biofuels
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Renewable Fuel Standard (RFS)
--Proposed Rule
--S. 1372: American Crude Oil Export Equality Act
----Amendment to Repeal Conventional Biofuel Category of RFS
--H.R. 702: A Bill to Adapt to Changing Crude Oil Market Conditions
---- Amendment to Repeal RFS

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Livestock Cloning/Product Labeling
--Discussions with EU on Animal Cloning

Genetically Engineered (GE) Animals
--Labeling
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
----Amendment on GE Salmon Labeling

Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
--Production Tax Credit Extension
--S.2089: American Energy Innovation Act

Funding for Biofuels
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Renewable Fuel Standard (RFS)
--Proposed Rule
--S. 1372: American Crude Oil Export Equality Act
----Amendment to Repeal Conventional Biofuel Category of RFS
--H.R. 702: A Bill to Adapt to Changing Crude Oil Market Conditions
----Amendment to Repeal RFS

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Biosimilars
--Biosimilar User Fee Act Implementation
--Coding
--Colombia Biologics Regulations
--Implementation of Affordable Care Act
--Interchangeability and Pharmacy Substitution
--Naming
--Reimbursement Policy

Funding for Centers for Disease Control and Prevention Vaccine Programs
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Vaccine Access/Financing

340B Drug Pricing Program
--Program Implementation & Oversight
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations

Diagnostics and Personalized Medicine Regulation and Oversight

Funding for FDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Biodefense Research, Development and Procurement Issues (Non-funding)

TransPacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
--Regulatory Transparency

Transatlantic Trade and Investment Partnership
--Intellectual Property Issues
--Regulatory Harmonization

Reimbursement for Innovative Products
--Medicare Part D Prescription Drug Program
--Medicare Part B Physician-Administered Products

Sequestration of PDUFA Fees
--S. 1413: FDA User Fee Protection Act
--HR 2725: Food and Drug Administration Safety over Sequestration Act of 2015

Drug Evaluation and Review
--Compassionate Use/Expanded Access
--Implementation of the FDA Safety and Innovation Act

Orphan Drug Act Tax Credit

Senate Innovation for Healthier Americans Initiative
--Biomarkers and Regulatory Science Improvements
--Combination Products
--Communication with Healthcare Professionals
--Expanded Access to Investigational Drugs
--Expedited Pathways
--FDA Hiring Flexibility
--FDA Management and Financial Accountability
--Information Disclosures
--Innovation Incentives
--Longitudinal Study of Chronic Diseases
--Patient Access to Approved Drugs
--Patient-Focused Drug Development
--Use of Real-World Evidence
--Vaccine and Anti-Microbial Resistance Product Development and Incentives
--PATH Act (Senate Discussion Draft)

House 21st Century Cures Initiative
--Vaccine and Anti-Microbial Resistance Product Development and Incentives
--ADAPT Act (House Discussion Draft)
--Biomarkers and Regulatory Science Improvements
--Communication with Healthcare Professionals
--Expanded Access to Investigational Drugs
--Expedited Pathways
--FDA Hiring Flexibility
--FDA Management and Financial Accountability
--Innovation Incentives
--Longitudinal Study of Chronic Diseases
--Patient Access to Approved Drugs
--Patient-Focused Drug Development
--Use of Real-World Evidence

Vaccines and Infectious Diseases - General

Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Government Price Reporting
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Gene Editing Technologies
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-----Report Language on Heritable Genetic Modification Restriction

NIH Precision Medicine Initiative

Antibiotic & Diagnostic Tax Credit
--H.R. 3539: Antibiotic & Diagnostic Innovation Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Health Resources & Services Administration (HRSA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-funding)

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--PATH Act (Senate Discussion Draft/Innovation for Healthier Americans Initiative)
--ADAPT Act (House Discussion Draft/21st Century Cures Initiative)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

NIH Precision Medicine Initiative

Funding for National Institutes of Health
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

Biodefense Research, Development and Procurement Issues (Non-funding)

House 21st Century Cures Initiative
--Longitudinal Study of Chronic Diseases

Senate Innovation for Healthier Americans Initiative
--Longitudinal Study of Chronic Diseases

Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations

Reimbursement for Innovative Products
--Medicare Part D Prescription Drug Program
--Medicare Part B Physician-Administered Products

House 21st Century Cures Initiative
--Patient Access to Approved Drugs

Senate Innovation for Healthier Americans Initiative
--Patient Access to Approved Drugs

Government Price Reporting
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Sarbanes Oxley Section 404 (b)
--Exemption for Emerging Companies

Capital Formation Investment Incentives
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
--H.R. 2179: PARTNER Act

Expansion of Exemption under SEC Regulation A
--H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act

Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
--Fostering Innovation Act (House Discussion Draft)

XBRL Exemption for Small Public Companies
--H.R. 1965: Small Company Disclosure Simplification Act

Capital Market Enhancements
--SEC Office of Small Business Policy Responsibilities
--H.R. 1525: Disclosure Modernization and Simplification Act
--H.R. 1675: Encouraging Employee Ownership Act
--H.R. 1723: Small Company Simple Registration Act
--H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act
--H.R. 2357: Accelerating Access to Capital Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Renewable Chemicals/Bio-based Products
--Expansion of Master Limited Partnerships to Renewable Chemicals
--New Production Tax Credit
--S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
--H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015

Biofuels
--Production Tax Credit Extension
--S.2089: American Energy Innovation Act

Research & Development Tax Credit Reforms
--Extension
--Permanency
--Refundable R&D Credit
--H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act

Capital Formation Investment Incentives
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
--H.R. 2179: PARTNER Act

Tax Reform
--Innovation Box/Patent Box

Orphan Drug Act Tax Credit

Inversions
--H.R. 2995/S.1910: Department of Financial Services and Related Agencies Appropriations Act for FY 2016

Antibiotic & Diagnostic Tax Credit
--H.R. 3539: Antibiotic & Diagnostic Innovation Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Biosimilars
--Colombia Biologics Regulations

Foreign Agricultural Biotechnology Laws and Regulations
--Asynchrony of International Approvals
--China Biotechnology Regulations
--EU Ag Biotech Policies and Regulations

TransPacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
--Regulatory Transparency

Transatlantic Trade and Investment Partnership
--Intellectual Property Issues
--Regulatory Harmonization

International Treaty on Plant Genetic Resources

Intellectual Property International Enforcement
--India

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SCI

16. Specific lobbying issues

Synthetic Biology
--H.R. 591: Engineering Biology Research and Development Act

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization